What is Lifesci Capital's Estimate for LQDA Q3 Earnings?

Key Points

• Analysts at Lifesci Capital have lowered their Q3 2025 EPS estimates for Liquidia Technologies to ($0.50), down from ($0.39), while the consensus estimate for the full year is ($1.51).
• In its most recent earnings report, Liquidia Technologies reported an EPS loss of ($0.49), missing estimates by ($0.06), despite a 141.5% year-over-year revenue increase to $8.84 million.
• Liquidia's stock has received a "Moderate Buy" rating from analysts, with a new average target price set at $31.40, indicating potential for growth amidst recent changes in analyst coverage and institutional investor activity.

Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) - Lifesci Capital reduced their Q3 2025 earnings per share (EPS) estimates for Liquidia Technologies in a research note issued on Tuesday, August 12th. Lifesci Capital analyst C. Jubinville now expects that the company will earn ($0.50) per share for the quarter, down from their previous estimate of ($0.39). The consensus estimate for Liquidia Technologies' current full-year earnings is ($1.51) per share. Lifesci Capital also issued estimates for Liquidia Technologies' Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($1.89) EPS.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.06). Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%.The business had revenue of $8.84 million during the quarter, compared to the consensus estimate of $3.90 million. Liquidia Technologies's revenue for the quarter was up 141.5% compared to the same quarter last year.

Several other research analysts have also recently weighed in on LQDA. Jefferies Financial Group initiated coverage on Liquidia Technologies in a research note on Friday. They set a "buy" rating and a $43.00 target price for the company. HC Wainwright boosted their price objective on Liquidia Technologies from $29.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, May 28th. Bank of America reduced their price objective on shares of Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Wednesday, June 11th. Oppenheimer set a $13.00 target price on shares of Liquidia Technologies and gave the stock an "underperform" rating in a research report on Monday, May 19th. Finally, Raymond James Financial boosted their price target on shares of Liquidia Technologies from $33.00 to $41.00 and gave the company a "strong-buy" rating in a report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Liquidia Technologies currently has a consensus rating of "Buy" and an average price target of $32.11.

Liquidia Technologies Price Performance

LQDA stock traded down $0.61 during trading hours on Friday, hitting $27.11. 2,242,984 shares of the stock traded hands, compared to its average volume of 1,785,113. The stock has a 50-day simple moving average of $16.50 and a 200 day simple moving average of $15.63. Liquidia Technologies has a one year low of $8.75 and a one year high of $28.00. The company has a market cap of $2.33 billion, a P/E ratio of -15.95 and a beta of 0.14. The company has a current ratio of 2.49, a quick ratio of 2.41 and a debt-to-equity ratio of 9.84.

Institutional Investors Weigh In On Liquidia Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in LQDA. Opaleye Management Inc. increased its holdings in shares of Liquidia Technologies by 9.5% during the 2nd quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company's stock valued at $30,838,000 after acquiring an additional 215,000 shares during the last quarter. Whitefort Capital Management LP raised its position in Liquidia Technologies by 16.8% in the 4th quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company's stock valued at $23,370,000 after purchasing an additional 285,220 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Liquidia Technologies by 17.3% during the fourth quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company's stock worth $20,698,000 after acquiring an additional 260,000 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Liquidia Technologies by 2.4% during the second quarter. Geode Capital Management LLC now owns 1,405,747 shares of the company's stock worth $17,517,000 after acquiring an additional 32,499 shares during the last quarter. Finally, Tyro Capital Management LLC bought a new stake in Liquidia Technologies in the second quarter valued at about $15,473,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Rajeev Saggar sold 5,327 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $14.28, for a total transaction of $76,069.56. Following the completion of the sale, the insider directly owned 271,413 shares of the company's stock, valued at $3,875,777.64. This trade represents a 1.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Scott Moomaw sold 4,797 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $14.28, for a total value of $68,501.16. Following the sale, the insider directly owned 223,231 shares of the company's stock, valued at $3,187,738.68. This trade represents a 2.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,277 shares of company stock worth $1,469,392 over the last ninety days. 30.10% of the stock is currently owned by corporate insiders.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).